pharma · Early Childhood Caries · Acute Myeloid Leukemia
University of Hong
The University of Hong Kong
University of Hong clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 42
- Drugs
- 71
- Patents
- 0
University of Hong projects
10 ClinicalTrials.gov programs sponsored by University of Hong.
University of Hong has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Atezolizumab
The University of Hong Kong
NSCLC Stage IIIB
1 trial -
Bomedemstat
The University of Hong Kong
Myelofibrosis
1 trial -
Capecitabine
The University of Hong Kong
Pancreatic Adenocarcinoma
1 trial -
Dapagliflozin 10mg Tab
The University of Hong Kong
Lupus Nephritis
1 trial -
Decitabine
The University of Hong Kong
Acute Myeloid Leukemia
1 trial -
Dietary
The University of Hong Kong
Colorectal Cancer
1 trial -
Interferon Beta-1B
The University of Hong Kong
COVID
1 trial -
Oral arsenic trioxide
The University of Hong Kong
Acute Myeloid Leukemia
1 trial -
Traditional Chinese acupuncture
The University of Hong Kong
Phonotraumatic Injuries
1 trial -
pembrolizumab
The University of Hong Kong
T-Cell Lymphoma
1 trial
Frequently asked questions
How many clinical projects does University of Hong have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.